An Open Label, Phase III Clinical Trial (Immunobridging Study) of INAVAC (Vaksin Merah Putih - UA-SARS-CoV-2 (Vero Cell Inactivated)) in Healthy Population Aged 12 to 17 Years Old

Tahapan Penelitian : Complete

Sponsor:

Mitra Pelaksana:

PT Biotis Pharmaceutical Indonesia, Universitas Airlangga

No Registry

INA-Q9EC6OB

Tanggal Input Registry : 01-01-2023

Tracking Information
Tanggal Antisipasi Studi	01-01-2023
Outcome Primer	not specified
Outcome Skunder

Descriptive Information
Judul Penelitian Popular	An Open Label, Phase III Clinical Trial (Immunobridging Study) of INAVAC (Vaksin Merah Putih - UA-SARS-CoV-2 (Vero Cell Inactivated)) in Healthy Population Aged 12 to 17 Years Old
Judul Penelitian Ilmiah	An Open Label, Phase III Clinical Trial (Immunobridging Study) of INAVAC (Vaksin Merah Putih - UA-SARS-CoV-2 (Vero Cell Inactivated)) in Healthy Population Aged 12 to 17 Years Old
Jenis Penelitian	Interventional
Intervensi	INAVAC (Vaksin Merah Putih - UA-SARS-CoV-2 (Vero Cell Inactivated))
Jumlah Subyek Penelitian	5

Recruitment Information
Eligibility Criteria	Inclusion Criteria: not specified Exclusion Criteria: not specified

Administrative Information
Nomor Persetujuan Etik	not specified
Nomor Persetujuan Material Transfer Agreement	Not applicable
Nomor Persetujuan Pelaksanaan Uji Klinik	PPUK/PPUB number
Other Study ID Numbers
Contact Person	not specified